Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Titel:
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Auteur:
Hoskin, Peter Sartor, Oliver O'Sullivan, Joe M Johannessen, Dag Clement Helle, Svein I Logue, John Bottomley, David Nilsson, Sten Vogelzang, Nicholas J Fang, Fang Wahba, Mona Aksnes, Anne-Kirsti Parker, Christopher